Oct 19, 2018 - Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
Oct 18, 2018 - Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
Oct 18, 2018 - Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Oct 16, 2018 - Names on the move ahead of the open.
Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
Oct 12, 2018 - Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
Oct 09, 2018 - Top Research Reports for JPMorgan, American Express & FedEx
Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out